Wallmark A, Alm R, Eriksson S
Proc Natl Acad Sci U S A. 1984 Sep;81(18):5690-3. doi: 10.1073/pnas.81.18.5690.
The PiZ genetic variant of alpha 1-antitrypsin in its homozygous form is associated with an increased risk for chronic lung and liver disease. About 5% of the population are carriers of one PiZ deficiency gene resulting in intermediate levels of plasma alpha 1-antitrypsin (PiMZ, PiSZ, PiPZ). We report the preparation of a hybridoma cell line, ATZ 11, produced by fusion of spleen cells from BALB/c mice immunized with a purified liver PiZ alpha 1-antitrypsin and Sp 2/0 Ag 14 mouse myeloma cells. ATZ 11 produces monoclonal antibodies (IgG1 kappa) specifically interacting with PiZ alpha 1-antitrypsin. These antibodies were used in an ELISA procedure permitting easy and accurate identification of PiZ gene carriers. The method is especially well-suited for studying large population samples concerning the putative relationship between intermediate alpha 1-antitrypsin deficiency and disease.
纯合形式的α1 - 抗胰蛋白酶的PiZ基因变体与慢性肺病和肝病风险增加相关。约5%的人群是一个PiZ缺陷基因的携带者,导致血浆α1 - 抗胰蛋白酶处于中等水平(PiMZ、PiSZ、PiPZ)。我们报告了一种杂交瘤细胞系ATZ 11的制备,它是由用纯化的肝脏PiZα1 - 抗胰蛋白酶免疫的BALB/c小鼠的脾细胞与Sp 2/0 Ag 14小鼠骨髓瘤细胞融合产生的。ATZ 11产生特异性与PiZα1 - 抗胰蛋白酶相互作用的单克隆抗体(IgG1κ)。这些抗体用于一种酶联免疫吸附测定程序,可轻松准确地鉴定PiZ基因携带者。该方法特别适合研究大量人群样本中关于中等α1 - 抗胰蛋白酶缺乏与疾病之间的假定关系。